ESPR
Esperion Therapeutics Inc
3.20$
+0.0%
vs. previous close
Closing price · As of: Jul 15, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 26.3% | 39.4% | 35.5% | 7.3% | 21.1% | 33.5% | 37.1% | 48.5% | 34.6% | 63.5% | 16.5% | 43.2% | 35.0% | |
| 73.7% | 60.6% | 64.5% | 92.7% | 78.9% | 66.5% | 62.9% | 51.5% | 65.4% | 36.5% | 83.5% | 56.8% | 65.0% | |
| 85.7% | 43.8% | 55.0% | 9.7% | 15.5% | 20.1% | 15.9% | 19.3% | 8.8% | 16.2% | 8.3% | 11.2% | 10.6% | |
| 158.0% | 97.9% | 92.5% | 30.5% | 59.8% | 77.4% | 16.5% | 66.2% | 48.0% | 47.9% | 24.6% | 53.8% | 39.7% | |
| 217.4% | 141.7% | 195.9% | 40.2% | 75.4% | 97.6% | 69.3% | 85.5% | 56.7% | 47.9% | 32.9% | 65.1% | 46.9% | |
| -143.7% | -81.1% | -131.4% | 52.5% | 3.5% | -31.0% | -6.4% | -34.0% | 8.6% | -11.4% | 50.6% | -8.2% | 18.1% | |
| 56.4% | 44.1% | 46.7% | 10.2% | 18.6% | 29.2% | 23.8% | 29.9% | 24.9% | 25.3% | 13.4% | 24.7% | 20.3% | |
| -193.7% | -121.4% | -174.7% | 44.3% | -83.9% | -57.2% | -30.8% | -62.2% | -15.4% | -35.9% | 37.8% | -31.5% | -1.3% | |
| -0.2% | -0.1% | -85.0% | 0.0% | – | -57.2% | – | – | – | – | 1.1% | – | – | |
| -193.7% | -121.4% | -174.7% | 44.3% | -83.9% | -57.2% | -30.8% | -62.2% | -15.4% | -35.9% | 36.7% | -31.5% | -1.8% | |
| -137.1% | -77.2% | -128.0% | 54.5% | -65.3% | -27.9% | -7.0% | -32.3% | 9.5% | -10.6% | 51.3% | -56.1% | 9.5% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: July 15, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.